Verici Dx Plc
LSE:VRCI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Verici Dx Plc
Gross Profit
Verici Dx Plc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Verici Dx Plc
LSE:VRCI
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$43.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$23.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$30.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$10.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
27%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$12.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
Verici Dx Plc
Glance View
Verici Dx Plc operates as a developer of advanced clinical diagnostics in organ transplant. The company is headquartered in Franklin, Tennessee and currently employs 8 full-time employees. The company went IPO on 2020-11-03. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The firm's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The firm develops tests to understand how a patient is responding to organ transplants. The firm's products include Clarava and Tuteva. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. The firm's subsidiary is Verici Dx Inc.
